Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v22-EN | Version v11-FR | |
---|---|---|
Language | English | French |
Date Updated | 2023-05-30 | 2023-01-27 |
Drug Identification Number | 00804789 | 00804789 |
Brand name | POTASSIUM PHOSPHATES | POTASSIUM PHOSPHATES |
Common or Proper name | POTASSIUM PO4 | POTASSIUM PO4 |
Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
Ingredients | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC | POTASSIUM PHOSPHATE DIBASIC POTASSIUM PHOSPHATE MONOBASIC |
Strength(s) | 236MG 224MG | 236MG 224MG |
Dosage form(s) | LIQUID | LIQUID |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 10ML 10LIVI | 10ML 10LIVI |
ATC code | B05XA | B05XA |
ATC description | I.V. SOLUTION ADDITIVES | I.V. SOLUTION ADDITIVES |
Reason for shortage | Requirements related to complying with good manufacturing practices. | Requirements related to complying with good manufacturing practices. |
Anticipated start date | ||
Actual start date | 2023-01-16 | 2022-09-02 |
Estimated end date | 2023-05-15 | 2023-05-26 |
Actual end date | 2023-05-09 | |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | Baxter item : 6750. | Baxter item : 6750 |
Health Canada comments |